C83.17 Mantle cell lymphoma, spleen

Name of the Condition

• Mantle cell lymphoma, spleen
• Also known as ICD-10 code C83.17

Summary

Mantle cell lymphoma, spleen, is a type of non-Hodgkin lymphoma characterized by the malignant proliferation of B-cells originating from the mantle zone of lymphoid follicles. It specifically involves abnormal growth of these cells in the spleen. This condition is part of the broader category of non-follicular lymphomas and may present with variable clinical behavior.

Causes

The exact cause of mantle cell lymphoma, spleen, remains unknown. It is thought to involve genetic mutations, such as the t(11;14)(q13;q32) translocation, which leads to overexpression of cyclin D1. Specific triggers or environmental factors are not well-defined, though research suggests potential links to immune system dysregulation.

Risk Factors

• Age: More common in older adults, typically over 60 years.
• Male gender: Slightly higher incidence in males.
• Family history of lymphoma.
• Prior exposure to radiation or certain chemicals.
• Chronic infections, such as hepatitis C or HIV.
• Immunosuppressive conditions or treatments.

Symptoms

• Swollen, painless lymph nodes.
• Unexplained weight loss.
• Fever.
• Night sweats.
• Fatigue.
• Loss of appetite.
• Abdominal pain or fullness (if spleen is involved).

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI), and laboratory tests. A definitive diagnosis typically requires a biopsy of the affected spleen or lymph node tissue, followed by histopathological examination and immunophenotyping to confirm the presence of mantle cell lymphoma. Additional tests, such as flow cytometry or molecular studies, may be used to identify characteristic genetic abnormalities.

Treatment Options

Treatment depends on the stage of the disease, overall health, and patient preferences. Options may include chemotherapy, immunotherapy, targeted therapy, or radiation therapy. In some cases, splenectomy (surgical removal of the spleen) may be considered. Clinical trials or novel therapies may also be available for eligible patients.

Prognosis and Follow-Up

Prognosis varies based on factors such as disease stage, response to treatment, and overall health. Regular follow-up appointments are essential to monitor for recurrence or progression. Follow-up may include physical exams, imaging studies, and laboratory tests to assess treatment response and detect any complications.

Complications

Potential complications include infection due to splenectomy or immunosuppression, anemia, thrombocytopenia, or transformation to a more aggressive lymphoma. Other risks may include treatment-related side effects, such as nausea, fatigue, or organ damage.

Lifestyle & Prevention

While specific prevention strategies are not well-established, maintaining a healthy lifestyle, avoiding known carcinogens, and managing chronic infections may help reduce overall cancer risk. Patients should follow their healthcare provider’s recommendations for vaccinations and infection prevention, especially if the spleen is removed or immune function is compromised.

When to Seek Professional Help

Seek medical attention if you experience persistent symptoms such as unexplained weight loss, fever, night sweats, fatigue, or abdominal pain. Early evaluation is important for timely diagnosis and treatment. Contact your healthcare provider if symptoms worsen or new symptoms develop.

Tips for Medical Coders

When coding for mantle cell lymphoma, spleen (C83.17), ensure the documentation specifies involvement of the spleen. Verify that the diagnosis aligns with the clinical presentation and that no other site-specific codes are more appropriate. Document any relevant details, such as biopsy results or treatment plans, to support code assignment. Follow coding guidelines for non-Hodgkin lymphoma and site-specific subcategories.